Keywords: Merck & Co, ElexoPharm, Licensing deal, Aldosterone synthase, cardiovascular disease

Germany’s ElexoPharm in CVD collaboration with Merck & Co, potentially worth 33.8 million euros

Article | 18 May 2010

Print This

US drugs giant Merck & Co has entered into a collaboration with German firm ElexoPharm GmbH to develop and commercialize ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in